Objective: To report results of a prospective trial of unilateral transcranial MRI-guided focused ultrasound (MRIgFUS) ablation of the cerebellothalamic tract in essential tremor (ET).
The thalamic ventral intermediate (Vim) nucleus is part of the network involved in essential tremor (ET) and the main stereotactic target for its treatment. It receives signals from the cerebellar output nuclei via the cerebellothalamic tract (CTT). 1 Both the high anatomic density of CTT fibers before diverging within the Vim and its larger distance to sensory thalamic nuclei are conceptual advantages of the CTT as a stereotactic target, 1 acknowledged by neurosurgeons performing subthalamotomies in the past. 2 Deep brain stimulation (DBS) studies indicate that the best stimulation effect on tremor is achieved in the white matter tracts caudal to the Vim rather than the Vim itself. 2, 3 Recently, transcranial MRI-guided high-intensity focused ultrasound (MRIgFUS) has been established to induce thermal coagulation lesions through intact skull and brain tissue under direct MRI guidance. 4 We have adopted the long-standing idea of subthalamotomy, i.e., CTT fiber tract ablation, for MRIgFUS treatment and report results from a prospective study of unilateral transcranial CTT MRIgFUS ablation in ET.
METHODS Standard protocol approvals, registrations, and patient consent. This study was designed as a prospective, uncontrolled, single-center interventional study, approved by the ethics committee of St. Gallen, and conducted in accordance with national and international law and good clinical practice. All participants provided written informed consent for participation.
The primary research question was to determine the efficacy and safety of unilateral MRIgFUS ablation of the CTT in ET. Patients with a diagnosis of ET according to established criteria and insufficient symptom control were included. Incision-less CTT ablation was achieved with the ExAblate Neuro system. The target structure within the posterior subthalamic area (PSA) was identified on 3T MRIs by a combination of direct targeting and atlas-based 5 coordinates. Interventions were performed as described previously. 4 At study visits before and 48 hours and 1, 3, and 6 months after intervention, full neurologic examination, Clinical Rating Scale for Tremors, Quality of Life in Essential Tremor, and manual dexterity (9-hole peg test) were documented. Trail-Making Test A and B were used as a combined measure for working memory, interference control, and visuomotor speed, and the MiniMental State Examination and Montreal Cognitive Assessment were used for cognitive screening.
Standardized tremor video recordings from all visits were rated in random order and blinded for evaluation time point by a movement disorder neurologist not involved in the treatments (S.R.S.). Participants 4 and 5 were unavailable for evaluations at months 1 and 3 but attended all other time points. The primary endpoint was change in hand tremor severity. Repeated-measures comparisons using mixed linear model statistics and least significant difference post hoc test, as well as the Wilcoxon signed-rank test, were calculated with SPSS version 22 (IBM, Armonk, NY) (see supplemental data and figure e-1 at Neurology.org).
RESULTS
The table summarizes interventional details of the participants who received unilateral MRIg-FUS ablation of the CTT contralateral to the mainly affected, treated hand. Postinterventional MRI confirmed exact lesion placement within the PSA (figure 1, A-C), and there was no sign of bleeding on susceptibility-weighted MRI. The initial mean lesion size on T1-weighted images (156.9 6 63.5 mm 3 ) decreased rapidly over time ( figure 1D) .
Clinically, the intervention had an immediate effect once a temperature .558C was reached (table) . There was a statistically significant, persisting reduction in Clinical Rating Scale for Tremors score over the 6-month follow-up (repeated-measures statistics; mean 6 SD at baseline vs 6 months after intervention; absolute reduction; 95% confidence intervals; repeated measures statistics): overall sum (43.8 6 9.8 vs 19.8 6 6.8; 224.0; 218.1 to 229.9; p , 0.001) and unilateral hand score on the treated side (14.3 6 4.9 vs 2.5 6 2.6; 211.8; 28.4 to 215.2; p , 0.001) (figure 2; see supplemental data for additional information).
Wilcoxon signed-rank (2-tailed) test showed a significant 52% improvement in quality of life over the same period (Quality of Life in Essential Tremor 
Patient 5 had an unwitnessed fall at home 4 weeks after the intervention with an occipital fracture, intracranial hematoma, and retrograde amnesia for the event, necessitating hospitalization with eventual full recovery. Retrospect analysis revealed an unexplained fall 6 months before the intervention in this patient. DISCUSSION This study is proof of principle that the exact and safe MRIgFUS ablation of white matter tracts within the PSA is potentially highly effective in ET.
Similar to MRIgFUS ET studies that targeted the Vim, [6] [7] [8] there is immediate symptom suppression once a thermal threshold is reached. Our data suggest that thermal susceptibility and lesion volumetric changes are similar between white matter tissue and previously studied nuclear structures. 6, 7 We did not observe imaging changes along white matter tracts outside the sonication target, indicating a confined local effect. In humans, the CTT has been localized histologically 1 and through advanced diffusion tensor imaging in vivo 3 within the PSA. 2 By using a targeting approach that combined atlas coordinates 5 and individual anatomic landmarks, we accommodated for the known anatomic variability in the PSA, explaining minor deviations from mean literature PSA coordinates. 2 Although these coordinates document that we aimed at the PSA, only postmortem analysis would allow ultimate target verification, as is true for all surgical targets that cannot be readily identified on MRI.
Clinical data presented here suggest highly efficacious symptomatic relief of unilateral hand tremor by contralateral CTT MRIgFUS ablation, as suggested by retrospective data. 9 The 83% efficacy in this study is comparable to MRIgFUS Vim lesions in open-label trials 6 (75% after 12 months; n 5 15), whereas a large double-blind MRIgFUS Vim study 8 reported a lower efficacy rate (47% after 3 months, n 5 76). In contrast to studies aiming at the Vim nucleus, 6, 8 we observed no transient or persistent paresthesia after CTT ablation, possibly related to the larger anatomic distance of the PSA to thalamic sensory structures. We provide evidence that CTT MRIgFUS ablation does not worsen manual dexterity and cognition, adding important information to the safety profile of this intervention.
Converging evidence points to a central origin for the fully reversible, intraprocedural vestibular symptoms observed by us and others 6 : Vim DBS for ET can affect vestibulothalamic pathways. 10 The steep gradient of acoustic energy of MRIgFUS also limits relevant effects to structures in the focus vicinity. The transient, mostly subclinical ipsilateral cerebellar side effects observed in part of our cohort are most likely a direct effect on the CTT or adjacent fiber tracts, as previously shown in PSA DBS. 3 These observations warrant cerebellar and vestibular monitoring in future trials.
After careful evaluation, we do not think that the fall in participant 5 is causally related to the study procedure. The timing of the event and video-documented gait and postural control examination before and after intervention do not indicate any balance changes due to the intervention. Nevertheless, preintervention gait instability requires careful risk-benefit evaluation before PSA MRIgFUS ablation.
Larger trials with a longer follow-up are needed to adequately assess the long-term safety and efficacy of MRIgFUS CTT ablation. Meanwhile, our study backs the growing evidence for the efficacy of MRIg-FUS ablation in ET and adds the CTT (Class IV evidence) as a suitable target.
AUTHOR CONTRIBUTIONS
S.R.S. was involved in conception and organization of the trial, executed the statistical analysis, and wrote the first manuscript draft. R.B., S.H.-L., N.W., and A.L. executed the study and critically reviewed the manuscript. K.P.B. was involved data analysis and critically reviewed the manuscript. P.N. was involved in data analysis and reviewed the manuscript. B.W. and E.M. were involved in the conception and execution of the study and critically reviewed the manuscript. G.K. was involved in conception, organization, and execution of the trial and critically reviewed the first draft and the manuscript.
STUDY FUNDING
No targeted funding reported. 
Subspecialty Alerts by E-mail!
Customize your online journal experience by signing up for e-mail alerts related to your subspecialty or area of interest. Access this free service by visiting Neurology.org/site/subscriptions/etoc.xhtml or click on the "E-mail Alerts" link on the home page. An extensive list of subspecialties, methods, and study design choices will be available for you to choose from-allowing you priority alerts to cutting-edge research in your field!
Get 10 AAN Practice Management Webinars for Less than $19 Each
The AAN is dedicated to helping neurologists improve their practices and delivery of quality care to their patients. Our popular Practice Management Webinars offer the latest expert information and insights to help you navigate through the changes that lay ahead in the new health care landscape. And they offer the flexibility to attend live webinars or access them on demand at a more convenient time.
Purchase webinars individually for $99 each, or subscribe to the complete series of 2017 webinars for only $189-that's less than $19 per webinar! See the list of webinars and subscribe at AAN.com/view/pmw17.
